SMMT
Summit Therapeutics Inc.
Biotechnology · Healthcare · United States
16.03
close · 2026-10-30
value
97
cheaper than peers97
quality
29
stronger fundamentals29
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 2 years ago | -0.6% | 99 |
| cash flow yield, 3 years ago | -0.3% | 98 |
| cash flow yield, 1 year ago | -1.1% | 97 |
| earnings yield, 3 years ago | -2.6% | 95 |
| earnings yield, 1 year ago | -1.9% | 94 |
| cash flow yield, latest year | -2.5% | 90 |
| earnings yield, 2 years ago | -6.2% | 84 |
| earnings yield, latest year | -9.0% | 76 |
| price to book | 20.19× | 7 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 3.2% | 55 |
| operating margin | 0.0% | 50 |
| return on equity | -192.5% | 13 |
3 of 4 measures available
Facts
| market cap | $13B |
| free cash flow | -$139.7M |
| employees | 265 |
| first trade | 2015-03-05 |
| next earnings | not reported |
| fundamentals updated | 2026-08-03 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.44 | -0.31 | -0.99 | -0.41 |
| free cash flow | -$323.6M | -$142.2M | -$76.9M | -$42.2M |
| net income | -$1.08B | -$221.3M | -$614.9M | -$78.8M |
| revenue | $0 | $0 | $0 | $705,000 |
| unusual items | $14.9M | -$1.6M | -$509.5M | -$12.6M |